GlassScriptPhysician profile
Brian A Adams
NPI 1013927904
$173,052.47
in general payments reported to CMS, 2019-2025
51 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $24K · 2021: $25K · 2022: $27K · 2023: $19K · 2024: $29K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $70K · Food and Beverage: $4,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $70,100.00 |
| Food and Beverage | $4,532.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $143,507.08 | 2020-2025 | Trintellix |
| Shire North American Group INC | $21,996.00 | 2019 | |
| Abbvie INC. | $1,669.00 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $664.20 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $642.67 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $555.76 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $494.77 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $283.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.68 | 2021-2025 | Jardiance |
| Corium, LLC | $212.95 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $200.55 | 2019-2025 | Trelegy Ellipta, Pediarix, Rotarix |
| Merck Sharp & Dohme LLC | $186.51 | 2021-2024 | Steglatro, Belsomra, Steglujan |
| Phathom Pharmaceuticals, INC. | $165.78 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.66 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $153.63 | 2023-2025 | Auvelity |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.